MAPK/ERK通路
结直肠癌
癌症研究
医学
信号转导
血管生成
转移
癌症
药理学
生物
内科学
细胞生物学
作者
Mehran Pashirzad,Reihaneh Khorasanian,Maryam Mahmoudi Fard,Mohammad-Hassan Arjmand,Hadis Langari,Majid Khazaei,Saman Soleimanpour,Majid Rezayi,Gordon A. Ferns,Seyed Mahdi Hassanian
出处
期刊:Current Cancer Drug Targets
[Bentham Science]
日期:2021-12-01
卷期号:21 (11): 932-943
被引量:17
标识
DOI:10.2174/1568009621666211103113339
摘要
The MAPK/ERK signaling pathway regulates cancer cell proliferation, apoptosis, inflammation, angiogenesis, metastasis and drug resistance. Mutations and up-regulation of components of the MAPK/ERK signaling pathway, as well as over-activation of this critical signaling pathway, are frequently observed in colorectal carcinomas. Targeting the MAPK/ERK signaling pathway, using specific pharmacological inhibitors, elicits potent anti-tumor effects, supporting the therapeutic potential of these inhibitors in the treatment of CRC. Several drugs have recently been developed for the inhibition of the MEK/ERK pathway in preclinical and clinical settings, such as MEK162 and MK-2206. MEK1/2 inhibitors demonstrate promising efficacy and anticancer activity for the treatment of this malignancy. This review summarizes the current knowledge on the role of the MAPK/ERK signaling pathway in the pathogenesis of CRC and the potential clinical value of synthetic inhibitors of this pathway in preventing CRC progression for a better understanding, and hence, better management of colorectal cancer.
科研通智能强力驱动
Strongly Powered by AbleSci AI